NCT03443960View on ClinicalTrials.gov

Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 29, 2018

Primary Completion Date

April 9, 2018

Study Completion Date

April 9, 2018

Conditions
Healthy Subjects
Interventions
DRUG

TNX-102 SL 5.6 mg

Subjects randomly assigned to this treatment will place 2 tablets simultaneously under the tongue until dissolved, and not to crush or chew them.

DRUG

Amrix 30 mg

Subjects randomly assigned to this treatment will swallow 1 capsules with a cup of water, and not to crush or chew it.

Trial Locations (1)

G1P 0A2

Quebec City, Québec

All Listed Sponsors
lead

Tonix Pharmaceuticals, Inc.

INDUSTRY

NCT03443960 - Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules | Biotech Hunter | Biotech Hunter